Vaccination to prevent varicella and shingles

被引:18
作者
Breuer, J [1 ]
机构
[1] Queen Mary Univ London, St Bartholomews & Royal London Sch Med & Dent, Dept Virol, London E1 1BB, England
关键词
chickenpox; varicella zoster; herpes zoster; vaccination; leukaemia;
D O I
10.1136/jcp.54.10.743
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Vaccination of healthy children against varicella using the live attenuated Oka vaccine has been available in Japan and south Korea for several years. In 1996, a programme of universal vaccination of children to prevent varicella was introduced in the USA and other countries, including Canada, Germany, and Sweden, have licensed the vaccine for use in healthy children. This article reviews the origin of the Oka vaccine and the evidence for vaccine safety and efficacy in children and adults. Universal vaccination of children and targeted vaccination of groups at risk of severe varicella are discussed. The possible use of the Oka vaccine to prevent zoster is reviewed, and initiatives to develop new varicella zoster virus vaccines are outlined.
引用
收藏
页码:743 / 747
页数:5
相关论文
共 65 条
[1]   Analysis of immune responses to varicella tester viral proteins induced by DNA vaccination [J].
Abendroth, A ;
Slobedman, B ;
Springer, ML ;
Blau, HM ;
Arvin, AM .
ANTIVIRAL RESEARCH, 1999, 44 (03) :179-192
[2]  
ARBETER AM, 1986, PEDIATRICS, V78, P742
[3]   Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates [J].
Argaw, T ;
Cohen, JI ;
Klutch, M ;
Lekstrom, K ;
Yoshikawa, T ;
Asano, Y ;
Krause, PR .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :1153-1157
[4]   IMMUNOLOGICAL EVIDENCE OF REINFECTION WITH VARICELLA-ZOSTER VIRUS [J].
ARVIN, AM ;
KOROPCHAK, CM ;
WITTEK, AE .
JOURNAL OF INFECTIOUS DISEASES, 1983, 148 (02) :200-205
[5]   EARLY IMMUNE-RESPONSE IN HEALTHY AND IMMUNOCOMPROMISED SUBJECTS WITH PRIMARY VARICELLA-ZOSTER VIRUS-INFECTION [J].
ARVIN, AM ;
KOROPCHAK, CM ;
WILLIAMS, BRG ;
GRUMET, FC ;
FOUNG, SKH .
JOURNAL OF INFECTIOUS DISEASES, 1986, 154 (03) :422-429
[6]   Live attenuated varicella vaccine [J].
Arvin, AM ;
Gershon, AA .
ANNUAL REVIEW OF MICROBIOLOGY, 1996, 50 :59-100
[7]  
ASANO Y, 1994, PEDIATRICS, V94, P524
[8]   THE IMMUNOGENICITY OF THE OKA MERCK VARICELLA VACCINE IN RELATION TO INFECTIOUS VARICELLA-ZOSTER VIRUS AND RELATIVE VIRAL-ANTIGEN CONTENT [J].
BERGEN, RE ;
DIAZ, PS ;
ARVIN, AM .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (05) :1049-1054
[9]   A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older [J].
Berger, R ;
Trannoy, E ;
Holländer, G ;
Bailleux, F ;
Rudin, C ;
Creusvaux, H .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 :S99-S103
[10]   Costs and benefits of routine varicella vaccination in German children [J].
Beutels, P ;
Clara, R ;
Tormans, G ;
VanDoorslaer, E ;
VanDamme, P .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 :S335-S341